The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
The Directors MUST buy shares to prove they back their own strategy. In any company in general, there is no point in having Directors/Senior Mgmt who are not invested.
The lab will increase share price when we get a contract/revenue. Once we do, I expect price to return to 30/40p area. IMO. DYOR.
At the AGM, the Directors said the lab would have annual revenue of £20M within 5 years. If that is achievable, and I'm sure it is, then the £500k raise is OK with me.
I would like to see more information on the lab service. They need to be moving faster in generating revenue. When they secure a customer (if they haven't already) then an RNS highlighting the fact the company is revenue-generating, for the first time in Val's history, will be a day to remember.
The milestone payment for Val201 was going to be $2M USD - the new lab will surpass that. No problem.
Would be good to see the Directors 'more invested'.
It has been a wild ride investing in Valirx in 2022.
This lab (contract research organisation) is what will transform this company imo. Suzy and Ken both have experience in revenue generating companies. They will be in full control of their work not having to subcontract. Plus Val will be generating revenue. They are on track. In Summer 2022 they said the new CRO would generate £20 million in 5 years.
What would happen if we get an RNS announcing a research contract (revenue) - we'll move to 60p/share imo.
Exciting times ahead! Don't miss out!
As Adam correctly pointed out:
201 (Thx) - £2m package first 1.5 yrs
Kings College - £400m milestone package
Obviously the Kings College tie-up is worth more - and progressing - hence the new lab is opening in Q1 2023.
Cytolytix presentation
Great
https://stream.brrmedia.co.uk/broadcast/6356701642a5e76c417b2e0d
Cancer Research UK helped develop VAL201. We owe it to CRU to bring it to market.
There must be a deadline on TheoremRX to deliver. The long delay is no good for anyone.
We now have a company handling press/marketing. Ready to go when TheoremRX deal completes.
We have a few weeks to wait ... it can go either way ... positive and we rise 100%-200% 30-45p IMO ... or negative and we can slump to 11-12p IMO.
Any move up on news will be large - 60% in one day IMO.
What a bitter sweet week.
Great to have rhubarbmk2 on board.
Plus two incredible additions to the board.
I can see this SP heading into the 30s this month and then, with time, the 60s.
To think, people were speculating the SP could fall to 7p. They missed out!
Recent placing now complete, so money in the back for at least two years. And no risk of another placing anytime soon!
£10million revenue within 5 years according to BOD at AGM.
Plus positive news flow coming in the next few weeks/months.